South San Francisco, CA, JUNE 25, 2019 — InterVene Inc. today announced it has raised $15 million in a Series B financing round. The company’s BlueLeaf® Endovenous Valve Formation System is the first catheter-based solution for deep vein reflux (DVR) — the failure of venous valves in the legs — that does not require an implant.
We mourn the passing of our co-founder, partner and friend, Andrew B. Craig III. He was essential to RiverVest’s founding in 2000 and inspiration to the firm’s high professional and personal standards. We will miss him as a mentor and friend, but forever be enhanced by the great example he set.
SAN DIEGO, May 20, 2019 /PRNewswire/ — Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular metabolism and energy production. The A round was led by New Enterprise Associates. Other participants in the round include Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners.
TOLEDO, Ohio, May 16, 2019 /PRNewswire/ — VentureMed Group, Inc., a privately-held medical device innovator in vessel preparation for interventional treatment of peripheral arterial disease (PAD) and stenoses of arteriovenous (AV) fistulas and grafts announced today that the Company will be relocating from its current facilities in the ProMedica Innovations Center in Toledo, Ohio to Minneapolis, Minnesota as the Company continues to develop and grow.
May 7, 2019 at 4:01 PM EDT
— Substantial reduction of patient reported symptoms and physician assessed signs and symptoms —
— Improvements also observed in atopic dermatitis, asthma and allergic rhinitis —
— Conference call and webcast today at 5:00 pm ET —
REDWOOD CITY, Calif., May 07, 2019 (GLOBE NEWSWIRE) — Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 1 results in patients with severe allergic conjunctivitis. Patients administered AK002 reported a 78% median improvement in ocular symptoms by Allergic Conjunctivitis Symptom (ACS) Score and a 71% median improvement in physician assessed signs and symptoms using the Ocular Symptom Score (OSS). In addition, patients suffering from comorbid atopic dermatitis, asthma and allergic rhinitis, despite treatment with currently available therapies, reported improvements in their symptoms while receiving AK002.
April 10, 2019
The gene therapy revolution that’s been sweeping through biotech isn’t just about humans anymore. A Penn-partnered biotech called Scout Bio has just picked up a $20 million round to step up its work on once-and-done therapies for common pet ailments. Read more
Financing to drive leadership in AAV vector-delivered one-time therapies for major chronic pet health conditions
Company supported by leading life sciences investors and an R&D collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania
Recent executive appointments provide global expertise in animal biologics clinical R&D, regulatory affairs, AAV manufacturing, and gene therapy research
PHILADELPHIA, April. 10, 2019 – Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, today announced a $20 million Series B financing to advance its pipeline and expand clinical and other operations. The financing was co-led by Digitalis Ventures’ Companion Fund and RiverVest Venture Partners, and was joined by new investor GreenSpring Associates as well as existing investors Frazier Healthcare Partners, Adage Capital Management and Correlation Ventures. In conjunction with the financing, Nancy Hong of RiverVest Ventures, Cindy Cole of Digitalis Ventures, and Aditya Kohli of Frazier Healthcare Partners will join the board alongside existing directors Mark Heffernan, Tachi Yamada, and Patrick Heron.
Maralixibat shows reductions in pruritus and serum bile acids in 48 week analysis of ICONIC Phase 2b study in Alagille syndrome patients
Long-term analysis of INDIGO study of maralixibat shows sustained response and growth improvements in progressive familial intrahepatic cholestasis type two (PFIC2)
FOSTER CITY, Calif. – Mar. 27, 2019 – Mirum Pharmaceuticals announced today that data from three of its programs will be presented at the International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress Center.
-Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
-Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder
San Francisco – March 25, 2019 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today reported positive proof of concept data from a Phase 2 multicenter, multiple-dose, dose-escalation trial of tildacerfont, an oral corticotropin-releasing factor type-1 (CRF1) receptor antagonist, for the treatment of patients with congenital adrenal hyperplasia (CAH). The Phase 2 results were presented in a late-breaking poster presentation at the Annual Meeting of the Endocrine Society (ENDO 2019), the premier conference for endocrine science and medicine.
— Financing to Advance Lead Anti-CD47 Antibody AO-176 in Ongoing Phase 1 Clinical Trial and Pipeline —
BRISBANE, CA and ST. LOUIS, MO, March 25, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder.
SAN FRANCISCO, March 8, 2019 /PRNewswire/ — Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that the abstract, titled “A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia,” has been selected for a late-breaking poster presentation at the 2019 Annual Meeting of the Endocrine Society (ENDO), the world’s largest event for endocrine science and medicine.